Summary Invasion through stromal extracellular matrix (ECM) is part of the complex, multistep process of tumour cell invasion and metastasis. Our group has previously demonstrated that calcium and calmodulin are important in another step in the metastatic cascadethat of attachment of cells to ECM. Interestingly, the non-steroidal anti-oestrogen tamoxifen (which also has calmodulin antagonist activity), used in the treatment of breast cancer and now in metastatic cutaneous melanoma, can inhibit the attachment of normal and neoplastic cells to ECM. In this study, we investigated whether such drugs, known to inhibit cell attachment, could also subsequently reduce their invasion through a layer of human fibronectin. We examined the ability of the specific calmodulin antagonist J8, tamoxifen and its two major metabolites, N-desmethyltamoxifen (N-des) and 4-hydroxytamoxifen (4-OH), as well as the pure anti-oestrogen ICI 182,780 and 17,Boestradiol to inhibit invasion of the human cutaneous melanoma cell line, A375-SM, uveal melanoma cells and uveal melanocytes. A375-SM cells and uveal melanoma cells showed a high level of invasion (15.2% and 33.7% respectively) compared with melanocytes (around 5%) under the experimental conditions used. Submicromolar concentrations of N-des, tamoxifen, J8 and 1 7,B-oestradiol significantly reduced the invasiveness of the A375-SM cell line. The uveal melanoma cells also showed similar inhibition, although at higher concentrations of these agents. 4-OH and ICI 182, 780 had little or no effect on invasion of A375-SM cells (these were not tested on uveal melanoma cells). All cells used in this study were found to be negative for type nuclear oestrogen receptors, reinforcing the possibility that tamoxifen and 17,-oestradiol can act via mechanisms unrelated to binding to classical oestrogen receptors to inhibit tumour cell invasion.
The prognosis for patients with either cutaneous (Garbe et al, 1995) or uveal melanoma (Bedikian et al, 1981; Rajpal et al, 1983) is poor once these tumours have metastasized. Metastatic spread involves several different stages and, in escaping from the primary tumour and in forming distal metastatic deposits, neoplastic cells need to attach to and subsequently invade through stromal ECM (Albini and Colacci, 1993 for review) . Metastatic melanoma cells express a greater range of adhesion molecules than their non-transformed precursor, the melanocyte (Mortarini and Anichini, 1993) . Initial attachment of cells to ECM proteins then leads to a reorganization of the cell cytoskeleton to form focal adhesions (Van Leeuwen et al, 1994) .
In recent years, our laboratory has investigated the role of signal transduction systems in the early stages of cell attachment and shown that attachment of melanoma cells to ECM proteins appears to involve intracellular signalling systems, in particular calcium and calmodulin (MacNeil et al, 1992 . We also demonstrated that tamoxifen and two of its major metabolites can inhibit cell attachment to ECM proteins. Our data suggest that the action of tamoxifen and metabolites in this respect is as a result of their ability to inhibit calmodulin activity at micromolar concentrations melanoma is particularly resistant to both approaches, and most single-agent therapies give merely a small extension in the disease-free interval (Legha, 1988; Feun et al, 1995) . Currently, the most promising approaches involve combined chemotherapy in which DNA-damaging agents, such as cisplatin, carmustin and dacarbazine, are administered with tamoxifen. Results to date suggest that tamoxifen has little to offer as a single-agent therapy compared with other agents already in use; however, when it is combined with other agents, a significant extension in the diseasefree interval has been achieved for patients with advanced metastatic melanoma (Del Prete et al, 1984; McClay et al, 1989 McClay et al, , 1992 Buzaid et al, 1991; Cocconi et al, 1992; Fierro et al, 1993; Reintgen and Saba, 1993) . It is not clear, at the time of writing, how tamoxifen works in combined chemotherapy regimens. There are few convincing data to indicate the presence of classical highaffinity nuclear oestrogen receptors (ERs) in cutaneous melanoma, in contrast to their common occurrence in breast cancer. However, recent data suggest that tamoxifen can inhibit human melanoma cell proliferation by interaction with type II oestrogen binding sites (type II EBS) in human melanoma cells (Piantelli, 1995) .
The aim of the present study was to investigate an alternative, putative tumour-inhibitory mechanism of tamoxifen. We investigated the ability of a specific calmodulin antagonist (J8) and of tamoxifen and its major metabolites to affect invasion of cutaneous and uveal melanoma cells through human fibronectin. We report that effective inhibition of cutaneous and uveal melanoma cell invasion in vitro can be achieved with submicromolar concentrations of J8, tamoxifen and N-des. Further, during the course of these studies, we found that the steroid hormone 17p-oestradiol could itself achieve a partial but significant inhibition of invasion at nanomolar concentrations in the cutaneous melanoma cell line.
Invasion of uveal melanoma cells could also be inhibited by 17p-oestradiol, but much higher micromolar concentrations were required.
MATERIALS AND METHODS
Fibronectin (from human plasma), trypsin-EDTA, Ham's F12 nutrient mix, Dulbecco's modified essential medium powder with phenol red indicator (DMEM), insulin, transferrin, collagenase type IA, ax-tocopherol (vitamin E), hydrocortisone, cholera toxin, Chelex-100, MCDB-153 medium, tamoxifen, nystatin, 12-phorbol-13-myristate acetate, 17p-oestradiol (water soluble) and trypan blue were obtained from Sigma Chemical (Poole, Dorset, UK). Penicillin/streptomycin, L-glutamine, vitamin concentrate, non-essential amino acids, Fungizone, sodium pyruvate, Eagle's modified essential medium with phenol red pH indicator (EMEM), liquid DMEM (with phenol red pH indicator) and RPMI-1640 medium (both with and without phenol red) were purchased from Gibco/BRL (Paisley, UK). Fetal calf serum was obtained from Globe Pharmaceuticals and neonatal calf serum from APP (West Midlands, UK). Transwell Inserts were obtained from Costar UK, High Wycombe, Buckinghamshire, UK. J8 [N-(6-amino-octyl-5-iodo-1 -naphthalene)] was a kind gift from Professor GM Blackburn prepared as described previously in MacNeil et al (1988) . N-des and 4-OH were gifts from Klinge Pharma, Munich, Germany. ICI 182, 4, 5, 5, 5 ,-pentafluoropentasulphinyl)-nonyllestra-1,3,5, (I0)triene-3, 171-diol 1) was a kind gift from Dr AE Wakeling at Zeneca (Alderley Park, Macclesfield, UK).
Oestrogen and progesterone receptors were examined using Abbott ER-ICA and PgR-ICA monoclonal kits (Abbott Laboratories, North Chicago, IL, USA).
Cell lines and culture conditions
The human cutaneous melanoma cell line A375-SM was a generous gift from IJ Fidler (USA) via MJ Humphries (University of Manchester, UK). These cells were maintained by serial passages in EMEM supplemented with penicillin (100 units ml-'), streptomycin (100 jig ml-'), Fungizone (1.2 ,tg ml-'), L-glutamine (2 jM), sodium pyruvate (1 mM), vitamin concentrate (1.5% of 100 x stock), non-essential amino acids (1%), sodium bicarbonate (0.187%) and fetal calf serum (10%) at 37°C in a 5% carbon dioxide/95% air atmosphere.
Human cutaneous fibroblasts were established from normal adult human dermis as follows: small pieces of split-thickness skin grafts from normal human skin were digested in 0.1% trypsin solution overnight at 4°C, followed by addition of 10% neonatal calf serum to end the action of the enzyme. The pieces of skin were washed, then epidermis was separated from the dermis. The dermis was then further washed and minced before being exposed to 0.05% collagenase in DMEM supplemented with 10% neonatal calf serum overnight at 37°C. The digested dermis was then spun at 200 g for 5 min, then resuspended in 10% DMEM. The fibroblasts were maintained by serial passages in DMEM supplemented with penicillin (100 units ml-'), streptomycin (100 jg ml-'), fungizone (0.6 jig ml-), L-glutamine (2 jM), sodium bicarbonate (0.375%) and fetal calf serum (10%) at 37°C at 5% carbon dioxide/95% air atmosphere and used within three passages.
Uveal melanoma cells were cultured from six tumour samples taken from freshly enucleated eyes containing posterior malignant melanomas of the uvea as previously described (Goodall et al, 1994) . Cells were cultured in DMEM-Ham's F12 (1:1) with 10% fetal calf serum, insulin (10 jig ml-'), transferrin (10 jig ml'), Lglutamine (2 mM), penicillin-streptomycin (100 jig ml-'), sodium bicarbonate (2.44 mg ml-'). Tumour cells were used within five passages. (All tumours used in this study had been removed by enucleation as they were considered clinically to be 'high risk'.)
Uveal melanocytes were cultured from the sclera and overlying outer choroid of freshly enucleated eyes containing posterior, malignant uveal melanomas as described previously (Goodall et al, 1994) . Cells were cultured in MCDB 153 (calcium concentration of 0.15 mM) supplemented with 2% chelated fetal calf serum, insulin (10 jig ml-'), transferrin (10 jig ml-'), hydrocortisone (2.8 jig ml-), L-glutamine (2 mM), penicillin -streptomycin (100 jg ml-'), nystatin (10 U ml-'), vitamin E (1 jig ml'), cholera toxin (100 ng ml'), bovine pituitary extract (50 jg ml-'), 12-phorbol-13-myristate acetate (10 nM). Uveal melanocytes were used within five passages.
Invasion assay
Transwell inserts, containing a polycarbonate filter with 8-jim-diameter pores randomly distributed over its surface, were inverted and 50 jil of human fibronectin (at 10 jig ml') added to the polycarbonate filter and left for 1 h at 37°C in a 5% carbon dioxide/95% air atmosphere. The transwells were then placed the correct way up in wells of a 24-well plate containing 400 jl of the serum-free medium, in which the cells had been cultured before the assay. All cell types used in the study were removed from the tissue culture flasks using 0.5 g 1-' trypsin-0.2 g 1-' EDTA, centrifuged at 250 g for 5 min and then resuspended in serum-free medium.
Cell suspensions (150 jl containing approximately 1.2 x 105 cells) plus an equivalent volume of serum-free medium (with or without drug) were then added to each transwell. Cells were then left for 20 h at 37°C in a 5% carbon dioxide/95% air atmosphere. The time of 20 h was chosen as, by this time, sufficient invasion had occurred, and it was below the doubling time of the cells used.
Following examination under the light microscope, all cells in the experiment were counted using the following techniques. The medium-cells-drugs mix was collected from the upper and lower chambers and replaced with an equivalent volume of trypsin-EDTA to remove the remaining cells from the assay. Cell number (of trypsinized cells plus any in the media in the upper and lower chambers) was then determined using a haemocytometer. Invaded cells were counted as those removed from the underside of the filter, free floating in the media of the 24-well plate or attached to the bottom of the well. Non-invaded cells were counted as those remaining in the transwell or attached to the upper surface of the filter. The percentage of the total amount of cells that had invaded through fibronectin over 20 h was then calculated.
When the effect of phenol red in the culture media (known to have oestrogenic properties) on invasion of the A375-SM cell line and uveal melanoma cells was examined, cells were cultured in RPMI-1640 media both with and without phenol red for 3 days before the invasion assay.
Dilution of drugs
J8 was made up as a 10 mm stock solution in 100% dimethylsulphoxide, tamoxifen, N-des and 4-OH were made up as a 10 mm stock solution in 50% ethanol -50% acetone, 17,-oestradiol was made up as a 10 mm stock solution in 1 x phosphate-buffered saline (PBS) (pH 7.4) and ICI 182,780 was made up to a 10 mm stock in ethanol and stored in the dark. ICI 182, 780 was further diluted in ethanol, as required, before a final 1:1000 dilution in serum-free medium. 17j-Oestradiol was stored at 4°C, then diluted when needed in serum-free medium. All other drugs were aliquoted and stored at -20°C and then diluted as required in serum-free medium.
diaminobenzidine -hydrogen peroxide chromagen. Cells were counterstained for negativity with 0.5% (aqueous) methyl green. In all cases, the human breast cancer cell line MCF-7 cultured for 7 days on glass coverslips was used as an assay positive control. MCF-7 cells cultured in the presence of 10-9 M oestradiol for 7 days were used as a positive control for the progesterone receptor assay.
Nuclear immunostaining for ER and PgR was assessed in the monolayers by two personnel (JWG and LOD) using a dualviewing attachment to an Olympus BH-2 light microscope at an ocular magnification of x40.
Statistics
Differences between means were tested for statistical significance using Student's paired or unpaired t-test as appropriate. A value of P < 0.05 was considered significant.
Cell viability
Cells were cultured in 24-well plates in the presence of the drugs in serum-free medium for 20 h before harvesting using trypsin-EDTA. Viability was assessed using trypan blue exclusion. All drugs were examined in four separate experiments.
Steroid receptor immunocytochemical staining
The A375-SM cell line, human uveal melanoma and melanocytes were examined for the presence of the ER, and the A375-SM cell line was co-tested for the presence of the progesterone receptor. Before staining, the cells to be tested were plated on sterile glass coverslips in full media (with phenol red); cells were then cultured under serum-free (with phenol red) conditions for 2 days before testing for the presence of oestrogen and progesterone receptors. Routine formaldehyde (3.7%) fixation (with post-fixation in methanol and acetone) and subsequent immunocytochemical staining was carried out using Abbott ER or Abbot progesterone receptor (PgR)-immunocytochemical kits (as described in Merkel and Osborne, 1988; Walker et al, 1988; Rayter, 1991) 
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RESULTS
Comparative ability of cells to invade through fibronectin
Under the conditions of the invasion assay described, uveal melanoma cells showed a significantly higher level of invasion (33.7 ± 4%, n = 16) than the A375-SM cell line (15 ± 1.5%, n = 37) (P < 0.0001). Both cell types were significantly more invasive than the melanocytes (5.1 ± 1. 1, n = 11) and the fibroblasts (0.5 ± 0.5, n = 6, P < 0.001 for all comparisons) (mean ± s.e.m., n = number of experiments). The uveal melanomas investigated in this study showed considerable intertumour variation, but much less assay to assay variation when cells from the same tumour were examined.
Effect of calmodulin antagonist J8 on cell invasion Figure 2A . Submicromolar concentrations of tamoxifen and N-des achieved approximately 50% inhibition; higher concentrations produced little further inhibition. 4-OH had no significant effect on A375-SM invasion up to the highest concentration tested (15 gM) as shown in Figure 2A .
With uveal melanoma cells, an essentially similar picture was seen, with tamoxifen and N-des significantly reducing invasionalbeit at higher concentrations (4-OH was not tested with these cells). The uveal melanocytes showed a very low level of invasion which was relatively resistant to the inhibitory effects of both tamoxifen and N-des (as illustrated in Figure 2B and summarized in Table 1 ).
Effects of 17p-oestradiol and the pure anti-oestrogen receptor antagonist, ICI 182, 780, on A375-SM cell invasion
To further investigate the mechanism of action of tamoxifen, we next examined the effects of 17p-oestradiol and the pure antioestrogen ICI 182,780 on A375-SM invasion. Figure 3 shows combined results of three experiments with each agent examined over a concentration range from 10 nm to 15 gM, and Table 1 shows the IC50 values obtained. We initially noticed a slight inhibitory effect of 17p-oestradiol in our standard culture conditions for the A375-SM cells. Figure 3A We next examined the ability of 17p-oestradiol to reduce the inhibitory effect of tamoxifen on the invasion of A375-SM cells.
Results of five such experiments in which cells were exposed to either tamoxifen, 17p-oestradiol or both for the 20 h duration of the assay are shown in Figure 4 . The concentration of tamoxifen used (5 gM) significantly reduced invasion by approximately 52%
(P = 0.004) in these four experiments; the deliberately high concentration of 17i-oestradiol (5 gM) used resulted in a 35% reduction in invasion (P = 0.002). The combined effects of the two agents was to reduce invasion by 28%, which was not significantly different to that resulting from either agent alone.
Next, we examined the effect of 170-oestradiol on A375-SM cells cultured in the absence of phenol red. To do this, we changed to RPMI-1640 medium (available both with and without phenol red). Following culture of cells in RPMI-1640 medium for 3 days before and during the invasion assay, 17p-oestradiol clearly inhibited A375-SM cell invasion. The presence or absence of phenol red in the medium, however, did not affect the invasiveness of the cells or their sensitivity to this steroid (as shown in Table 2 ). Accordingly, data in the presence and absence of phenol red were combined as illustrated in Figure 3A , which shows that cells were clearly more sensitive to 17f-oestradiol in RPMI-1640 than in EMEM medium. Thus, in RPMI-1640, 1 nM 17,-oestradiol decreased invasion by 34 ± 7.9% (P = 0.001), with a maximum reduction of 61.1 ± 3.6% (P < 0.0001) achieved at a concentration of 5 ,UM (data based on five combined experiments).
Uveal melanoma cells were largely unresponsive to any antiinvasive effects of 17[B-oestradiol until very high concentrations of steroid were used -as shown in Table 2 . This was irrespective of whether cells were examined in DMEM-F12 medium with phenol red or RPMI-1640 without phenol red. The pure anti-oestrogenic compound ICI 182,780 had no significant effect on the invasion of the A375-SM cells up to 5 ,UM, but, by 15 gM, it had reduced invasion by 36 ± 14% based on three combined experiments as shown in Figure 3B and summarized in Relationship between ability of drugs to inhibit invasion, bind to oestrogen receptor and inhibit calmodulin activity Table 3 compares the ability of the drugs tested to inhibit invasion of A375-SM cells (tested in this study) with their previously reported ability to inhibit calmodulin activity and bind to the oestrogen receptor (reported elsewhere). The table shows that, whereas J8, tamoxifen and its two major metabolites were equipotent (IC50 of 2-3 gM) in their ability to inhibit calmodulin, their ability to inhibit invasion and to bind to the oestrogen receptor varied considerably. The two drugs that had least effect on cell invasion 780) were those with the greatest affinity for the ER. The three drugs that showed ability to inhibit cell invasion at submicromolar (IC50 of 0.1-0.5 JM) concentrations (J8, tamoxifen and N-des) were equipotent in their ability to inhibit calmodulin activity (IC50 of 2-3 JM) but varied in their ability to bind to classical oestrogen receptors. Finally, partial inhibition (20-25% in EMEM and 49% in RPMI-1640 media) was also British Journal of Cancer (1997) 75(6), 860-868 achieved with 17p-oestradiol at submicromolar concentrations (around 0.1 gM).
DISCUSSION
The main aim of this study was to examine whether a specific calmodulin antagonist (J8) could reduce melanoma cell invasion in vitro. In relation to this, we also wished to test whether tamoxifen might reduce melanoma cell invasion, possibly by acting as a calmodulin antagonist rather than through its ability to compete with oestrogen binding to oestrogen receptors.
Submicromolar concentrations (non-toxic) of J8, tamoxifen and N-des effectively reduced the invasion of a human melanoma cell line, A375-SM, while micromolar concentrations inhibited cells established from primary uveal melanoma. Additionally, we found that the actions of tamoxifen could not be fully reversed by the addition of a high concentration of 17p-oestradiol and that, paradoxically, 170-oestradiol itself produced a significant inhibition of A375-SM invasion. To the best of our knowledge, these are novel observations and may prove to be of clinical relevance.
The invasion of cells through a layer of ECM, as in this in vitro assay, is only part of the complex process of metastatic spread which occurs in vivo (as reviewed in Albini and Colacci, 1993) . Nevertheless, such in vitro invasion assays provide a relatively simple method for examining differences in invasive phenotype between neoplastic and normal cells and for investigating the effects of pharmacological agents on such invasion.
The in vitro invasion assay used for this study proved sufficiently sensitive to allow differences in invasive phenotypes to be observed between malignant cells, melanocytes and fibroblasts. Cells cultured from human uveal melanoma tumours also proved significantly more invasive than their normal non-transformed counterpart, the uveal melanocyte. However, it was noticeable that some invasion was observed with uveal melanocytes under the conditions of this assay. Fibronectin is one of several substrates to which the uveal melanoma will attach in preference to plastic . For cells to traverse the layer of fibronectin, they would need to bind to it, secrete degradative enzymes and move through it (Albini and Colacci, 1993; Edward and MacKie, 1993) . In contrast, cutaneous fibroblasts were relatively poor at invading through fibronectin (< 1% showing any ability to invade under the conditions of this assay).
With the relatively low level of invasion seen with the uveal melanocytes (around 5%), it was sometimes technically difficult to determine the effect of agents on their invasion; however, we would have to conclude that there was no convincing effect of J8 or N-des on uveal melanocyte invasion in these experiments. Relatively high concentrations of tamoxifen did reduce invasion.
The A375-SM cell line was generally more sensitive than the uveal melanoma cells to the inhibitory effects of J8 and tamoxifen.
Uveal melanoma cells showed considerable intertumour variation which may reflect the metastatic nature of such uveal melanomas in vivo. In most cases, metastatic spread occurs within 5 years of initial diagnosis, but metastatic spread has, in exceptional cases, been recorded up to 42 years after diagnosis (Sheilds et al, 1985) . Once detectable metastases have formed, the patient is unlikely to survive for more than a few months (Gragoudas, 1991) .
In the current study, four out of six tumours were composed predominantly of epithelioid cells (which have the worst clinical prognosis; Paul et al, 1962) . Unfortunately, given the small number of tumours used and the predominance of epithelioid morphology of tumours in the current study, we are unable to comment on any possible relationship between tumour morphology in vitro and invasive properties in vivo.
Under conditions parallel to those used in the invasion assays, we were unable to find any evidence of classical high-affinity oestrogen receptors or indeed progesterone receptors (which would have been indicative of active oestrogen receptors) in any of the cells used in this study.
The study demonstrates that J8, tamoxifen, N-des and 17f-oestradiol were all capable of significantly reducing cell invasion through fibronectin in vitro. To what extent can we make any deductions about the mechanism of action of these drugs? The calmodulin antagonist J8 inhibits calmodulin-dependent phosphodiesterase with an IC50 of around 3 gM, while concentrations exceeding 1000 gM are required before any significant inhibition of protein kinase C or transglutaminase activity is seen (MacNeil et al, 1988) . This contrasts to other less specific calmodulin antagonists such as the substituted naphthelene sulphonamide W7 which can also, at around 200-300 gM, inhibit protein kinase C and transglutaminase in vitro (MacNeil et al, 1988) . Thus, actions of J8 on invasion through fibronectin are more likely to be attributable to inhibition of calmodulin than to inhibit, for example, protein kinase C or transglutaminase.
However, calmodulin itself mediates many different actions of calcium in the cell (e.g. cell proliferation, microtubule disassembly and secretion of agents from the cell (as reviewed in Tomlinson et al, 1984) . In the current invasion assay, the relatively short duration (20 h) allows us to exclude any major effect of calmodulin on cell proliferation. Cells traversing a layer of fibronectin might well be secreting degradative enzymes -calmodulin may influence this. We have also documented that calmodulin antagonists will block melanoma cells attaching to ECM proteins; and, here, we suspect that calmodulin is involved in the transmission of the ECM-receptor signal into the cell which leads directly or indirectly to the reorganisation of the cytoskeleton. The invasiveness of the A375-SM cells to J8 proved to be more sensitive (IC50 value of 0.2 JM) than we would have predicted from the potency of J8 as an inhibitor of calmodulin (IC50 value of 3 gM based on its ability to inhibit calmodulin-dependent phosphodiesterase). However, the former assay is of 20-h duration and the latter of only 15 min, which may explain the tenfold difference between the performance of the drug in the two assays. The situation is potentially further complicated by reports that calmodulin can bind to and activate the oestrogen receptor with tamoxifen, preventing this activation (Castoria et al, 1988 (Castoria et al, , 1993 Bouhoute and Leclerq, 1992) Tamoxifen has a particularly complex pharmacology. If it is acting as a competitive inhibitor of oestrogen binding to the ER, then addition of excess oestradiol should reverse its action. However, this was not the case in this study as only a partial and insignificant reversal was achieved with oestradiol -indeed, the steroid itself caused a partial inhibition of invasion. While tamoxifen is effective in the treatment of oestrogen receptor positive breast tumours, some benefit is seen, surprisingly, in approximately 10% of receptor negative patients (Jordan et al, 1988) . This indicates the possible involvement of an alternative inhibitory mechanism. In this light, a type II EBS, distinct from the oestrogen receptor, was discovered (Sutherland et al, 1980) which can bind tamoxifen (although not the drug ICI 182,780) and may be induced in both oestrogen receptor negative breast cancer and melanoma cells inhibited by tamoxifen (Piantelli et al, 1995) . Thus, one explanation for our data is that some of the actions of tamoxifen may have been as a result of its actions on a type II EBS rather than on a classical nuclear oestrogen binding site. This is supported, to some extent, by our finding that 4-OH (which has a higher affinity than tamoxifen for the ER) was relatively ineffective in blocking invasion of A375-SM melanoma cells, whereas Ndes (which has a lower affinity than tamoxifen for the ER) was as potent as tamoxifen in blocking invasion.
The natural ligand for the type II EBS is methyl -p -hydroxyphenylactate (Makaveriech et al, 1988) , and it is thought that these receptors can be occupied by flavenoid-like molecules (Piantelli et al, 1995) . The type II EBS has a lower affinity but higher capacity for oestrogen than the classical oestrogen receptors -they have an apparent dissociation constant of around 20 nm for oestrogensand we found that nanomolar (10-100 nM) concentrations of 17p-oestradiol inhibited invasion. In this study, the invasive activity of both A375-SM and uveal melanoma cells was unaffected by the presence of phenol red (which has oestrogenic properties), also suggesting that classical oestrogen receptors are not relevant to the invasive properties of either cell type. Uveal melanoma cells were largely unaffected by physiologically relevant concentrations of 17p-oestradiol in both media examined; in contrast, A375-SM cells showed an initial inhibitory response to nanomolar concentrations of 17p-oestradiol which were clearly medium (but not phenol) dependent. This illustrates the difficulties of unmasking such a sex steroid response and may explain why this has not been reported previously.
Tamoxifen can also influence growth factor production, e.g. by stimulating the proliferation inhibitory factor TGF-P and inhibiting the mitogenic factor TGF-oc (Noguchi et al, 1993) , and these effects of tamoxifen should also be considered. Can we draw any conclusions about whether the actions of tamoxifen and its two major metabolites inhibit cell invasion via their ability to inhibit calmodulin activity? Whereas N-des and 4-OH differ in their affinity for the classical oestrogen receptor, they are equipotent with tamoxifen in their ability to inhibit calmodulin-dependent phosphodiesterase in vitro and to inhibit melanoma cell attachment to matrix proteins in vitro (MacNeil et al, 1993) . If all three compounds were inhibiting invasion via any anti-calmodulin activity, then we would expect the three to be roughly equipotent in these assays. However, we found tamoxifen and N-des to be equipotent in inhibiting invasion whereas 4-OH was relatively ineffective in inhibiting invasion of A375-SM cells (this metabolite was not tested for its effect on uveal melanoma cells). Also, the concentrations of tamoxifen and N-des required to reduce invasion for the A375-SM cells were submicromolar which is unexpectedly more potent than we would expect of their action if they were working as calmodulin antagonists (but, as with J8, this may be explained by the longer duration of the invasion assay). Against this, however, the concentrations of tamoxifen and N-des required to inhibit invasion of the uveal melanoma cells were of the same order as would be expected if they were acting as a calmodulin antagonist.
It was noticeable that tamoxifen and N-des produced a partial inhibition of invasion at nanomolar concentrations. No further inhibition was seen until micromolar concentrations were used. There are several possible explanations for these observations. If the two agents are acting via type II EBS, then perhaps nanomolar concentrations saturate the receptors, causing the initial sharp decrease in invasion. This would then account for the subsequent plateau phase. Micromolar concentration of the agents may then cause further inhibition by another mechanism, e.g. involving inhibition of calmodulin activity (MacNeil et al, 1988) or indeed inhibition of protein kinase C (O'Brian et al, 1985; Gundimeda et al, 1996) . A further possibility is a heterogeneous population of cells with one subpopulation highly sensitive to inhibition by tamoxifen and N-des and a more resistant subpopulation. Further investigations are needed in this area to clarify this observation.
In summary, our findings with these drugs do not allow us to draw firm conclusions about their mechanism of action in melanoma. In the case of J8, it is likely that this drug is acting by inhibiting calmodulin, but we are not able to say from this study which intracellular action of calmodulin is relevant to invasion.
With tamoxifen and its metabolites, it is highly unlikely that they are inhibiting invasion via any action on classical oestrogen receptors, although our data would be consistent with an action on a type II oestrogen receptor binding site. With regard to 17j-oestradiol, again it is unlikely that this is an action on a classical oestrogen binding site, but action on a type II EBS cannot be excluded.
This study yields novel data showing three approaches to the inhibition of melanoma tumour cells in vitro -the use of specific calmodulin antagonists, the use of tamoxifen and one of its metabolites and the use of an oestrogen. Findings with tamoxifen and 173-oestradiol are particularly interesting in view of the recent reported benefit of tamoxifen in combined chemotherapy regimens (Cocconi et al, 1992) and epidemiological data supporting a female survival benefit in metastatic melanoma (Vossaert et al, 1992; Stidham et al, 1994; Garbe et al, 1995; Karakousis and Driscoll, 1995) .
This area is undoubtedly complex. We suggest that our findings with tamoxifen and 1713-oestradiol are timely and merit further investigation because of their potential relevance to the understanding and treatment of metastatic disease in melanoma.
